Haisco Pharmaceutical Group (002653.SZ) has obtained two indications for the innovative drug HSK44459 cream, with IND applications accepted.

Haisco Pharmaceutical Group (002653.SZ) announced that the company has received a "Notice of Acceptance" from the National Medical Products Administration for the drug "HSK44459 Cream". HSK44459 Cream is a new drug independently developed by the company with proprietary intellectual property rights for the treatment of psoriasis and eczema. Preclinical study results have shown that the drug has a clear target, definite efficacy, and good safety profile. It is a small molecule drug with great potential for development, high benefit-risk ratio for clinical use, broad clinical application prospects, and is expected to become an effective treatment for psoriasis and eczema, addressing the current lack of treatment options.